Modernland Realty Ltd
MDLN
$34.26
+5.16%
Medline Inc. is the largest provider of medical-surgical products and supply chain solutions in the United States, offering a vast catalog of Medline-branded and third-party products to major health systems. As a market leader with over 45,000 employees and a dominant domestic footprint, the company leverages its scale and logistics network to serve as a prime vendor for many customers. The current investor narrative centers on the company's recent IPO in December 2025, its growth trajectory, and near-term operational challenges, including a distribution center fire and FDA safety concerns that have created uncertainty and weighed on the stock price.…
MDLN
Modernland Realty Ltd
$34.26
Related headlines
Investment Opinion: Should I buy MDLN Today?
Rating: Hold. The stock is a Hold because while the consensus is Buy with a 30% upside to the average target, the near-term operational issues and margin compression create significant uncertainty. The thesis is that Medline's dominant market position and revenue growth will eventually overcome these headwinds, but the timing is unclear.
Sign up to view all
MDLN 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While revenue growth is strong, margin compression and operational risks temper optimism. The stock is trading near its 52-week low, suggesting limited downside but also weak momentum. If margins recover and revenue growth sustains, the stock could re-rate higher; if not, it may test new lows. Key factors to watch are margin trends and resolution of FDA issues.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Modernland Realty Ltd's 12-month outlook, with a consensus price target around $44.62 and implied upside of +30.2% versus the current price.
Average Target
$44.62
0 analysts
Implied Upside
+30.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$34 - $55
Analyst target range
The target price range spans from a low of $34.00 to a high of $55.00, with the low near the current price suggesting some analysts see limited downside, while the high implies a 60.5% upside. The wide spread of $21.00 reflects high uncertainty, driven by recent operational disruptions and regulatory concerns. Recent ratings actions have been mostly reaffirmations of positive stances, with no downgrades, but the stock's underperformance relative to the S&P 500 (relative strength of -10.3% over 1 month) suggests that analysts may be slow to adjust targets downward. The consensus implies that the market is pricing in a recovery, but the wide range indicates significant risk.
Drowning in data?
Find the real signal!
Bulls vs Bears: MDLN Investment Factors
The bear case currently holds stronger evidence, driven by margin compression, operational disruptions, and a clear downtrend. However, the bull case is supported by accelerating revenue growth, a dominant market position, and a consensus Buy rating with 30% upside. The central tension is whether Medline can resolve its operational issues and restore margins to historical levels; if it does, the stock could re-rate higher, but continued disruptions could push it lower. The wide analyst target range ($34-$55) underscores this uncertainty.
Bullish
- Revenue Growth Accelerating: Q1 2026 revenue grew 10.66% YoY to $7.352B, up from 8.5% growth in Q2 2025. This acceleration suggests strong demand for Medline's medical-surgical products despite operational headwinds.
- Analyst Consensus is Buy: With 26 analysts, the consensus recommendation is 'buy' (mean 1.56 on a 1-5 scale). The average price target of $44.62 implies 30.2% upside from the current price of $34.26, indicating Wall Street sees value.
- Strong Balance Sheet Liquidity: Current ratio of 4.29 indicates ample short-term liquidity to weather disruptions. Debt-to-equity of 1.17 is manageable for a company of this scale, and free cash flow TTM of $1.525B provides a cushion.
- Dominant Market Position: As the largest US provider of medical-surgical products with 45,000 employees and over 30 manufacturing facilities, Medline's scale and prime vendor relationships create high switching costs and pricing power.
Bearish
- Stock in Downtrend, Near Lows: MDLN has fallen 32.7% from its 52-week high of $50.876 to $34.26, trading at only 12.6% of its 52-week range. The stock is down 31.2% over 6 months, reflecting persistent selling pressure and negative sentiment.
- Margin Compression Significant: Gross margin fell from 25.1% in Q2 2025 to 22.65% in Q1 2026, a 245 basis point decline. Operating margin dropped from 9.13% to 5.74% in the same period, indicating cost pressures and operational inefficiencies.
- Operational Disruptions and FDA Concerns: A major distribution center fire and an FDA warning letter about homecare bed safety risks create near-term financial and reputational headwinds. These events could lead to lost sales, increased costs, and regulatory scrutiny.
- Negative PEG Ratio: The PEG ratio of -4.96 signals that earnings growth expectations are not supported by current momentum. Trailing EPS of $0.034 is extremely low, making the trailing PE of 29.37x look expensive relative to growth.
MDLN Technical Analysis
MDLN is in a clear downtrend since its IPO, with the stock price falling from a 52-week high of $50.876 to a current price of $34.26, representing a 1-year decline of 32.7% (based on the 52-week range). The stock is trading at only 12.6% of its 52-week range (calculated as (34.26 - 32.485) / (50.876 - 32.485)), indicating it is near the lows and reflecting persistent selling pressure. This positioning suggests the market is pricing in significant negative sentiment, but also potential value if the company can stabilize.
Beta
—
—
Max Drawdown
-34.8%
Largest decline past year
52-Week Range
$32-$51
Price range past year
Annual Return
—
Cumulative gain past year
| Period | MDLN Return | S&P 500 |
|---|---|---|
| 1m | -7.9% | +3.6% |
| 3m | -7.4% | +2.7% |
| 6m | -31.2% | +11.4% |
| 1y | — | +18.7% |
| ytd | -15.7% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDLN Fundamental Analysis
Medline's revenue has shown steady growth, with Q1 2026 revenue of $7.352 billion, up 10.66% year-over-year from $6.644 billion in Q1 2025. However, the growth rate has decelerated from the 8.5% YoY growth seen in Q2 2025 (revenue of $6.886 billion vs. $6.185 billion in Q2 2024) to the current 10.66%, indicating a mixed trend. The company's gross margin has compressed from 25.1% in Q2 2025 to 22.65% in Q1 2026, reflecting cost pressures and operational challenges, while operating margin fell to 5.74% from 9.13% in the same period.
Quarterly Revenue
$7.4B
2026-03
Revenue YoY Growth
+10.7%
YoY Comparison
Gross Margin
22.7%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDLN Overvalued?
Given that Medline is profitable with a trailing EPS of $0.033984, the PE ratio is the primary valuation metric. The trailing PE stands at 29.37x, while the forward PE is 21.77x, implying the market expects earnings growth of about 35% (calculated as (29.37/21.77 - 1)). This gap suggests optimism about future profitability improvements, but the negative PEG ratio of -4.96 indicates that growth expectations are not supported by current earnings momentum.
PE
29.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 24x~48x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are elevated due to margin compression and high leverage. Gross margin fell from 25.1% in Q2 2025 to 22.65% in Q1 2026, and operating margin dropped from 9.13% to 5.74%, indicating cost pressures. Debt-to-equity of 1.17 is manageable but interest expense of $165M in Q1 2026 weighs on net income. The company's reliance on continued growth to justify its forward PE of 21.77x is risky if revenue decelerates. Free cash flow of $1.525B provides some cushion, but the negative PEG ratio (-4.96) suggests earnings growth is not keeping pace with valuation.
FAQ
The key risks are: 1) Operational: the distribution center fire could disrupt supply and increase costs. 2) Regulatory: the FDA warning letter on homecare beds could lead to recalls or restrictions. 3) Financial: margin compression and high debt (D/E of 1.17) could pressure earnings. 4) Market: the stock is in a downtrend and underperforming the S&P 500, which could continue. The most severe risk is a prolonged operational crisis that erodes customer trust and market share.
The 12-month forecast is mixed. The bull case (30% probability) targets $45-$55, the base case (45% probability) targets $38-$45, and the bear case (25% probability) targets $30-$34. The most likely scenario is the base case, with the stock trading around $40-$45, assuming gradual margin recovery. The key assumption is that operational issues are resolved without lasting damage. If revenue growth stays above 10% and margins improve, the stock could reach the high $40s.
MDLN is trading at a trailing PE of 29.37x, which is high relative to its earnings growth, but the forward PE of 21.77x is more reasonable. The PEG ratio of -4.96 indicates that the market expects negative growth, which is not the case. Compared to peers, the PS ratio of 1.20 is moderate. The stock is trading near its 52-week low, suggesting it may be undervalued if the company can recover. However, the market is pricing in significant risk, so it is fairly valued given the uncertainty.
MDLN is a Hold for most investors. The stock offers 30% upside to the average analyst target of $44.62, but the downside risk to the 52-week low of $32.485 is only 5%. However, the negative PEG ratio and margin compression suggest that earnings growth may not justify the valuation. For investors with a high risk tolerance and a long-term horizon, it could be a good buy if operational issues resolve. For conservative investors, it's better to wait for signs of margin stabilization.
MDLN is better suited for long-term investment, given its dominant market position and growth potential. The stock is volatile, with a beta not provided, but its 32.7% decline from the high shows significant short-term risk. The dividend yield of 1.52% provides some income, but the payout ratio of 44.7% is moderate. For short-term traders, the stock is in a downtrend and could continue to fall, so it's not ideal. A minimum holding period of 2-3 years is recommended to allow operational issues to resolve and the company to realize its growth potential.
